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Abstract: Preparation of optically-pure derivatives of 2-hydroxy-2-(3-hydroxyphenyl)-2-phenylacetic
acid of general structure 2 was accomplished by enzymatic hydrolysis of the
correspondent esters. A screening with commercial hydrolases using the methyl ester of
2-hydroxy-2-(3-hydroxyphenyl)-2-phenylacetic acid (1a) showed that crude pig liver esterase
(PLE) was the only preparation with catalytic activity. Low enantioselectivity was observed with
substrates 1a–d, whereas PLE-catalysed hydrolysis of 1e proceeded with good enantioselectivity
(E = 28), after optimization. Enhancement of the enantioselectivity was obtained by chemical
re-esterification of enantiomerically enriched 2e, followed by sequential enzymatic hydrolysis with
PLE. The preparation of optically-pure (S)-2e was validated on multi-milligram scale.
Keywords: esterase; stereoselective; ester hydrolysis; antimuscarinic agents; pig liver esterase (PLE)
1. Introduction
Enzymatic hydrolysis of chiral esters using carboxylesterases is an established method for
obtaining kinetic and dynamic resolution [1–5]. A number of stereoselective carboxylesterases
is nowadays available, and troublesome application such as the hydrolysis of spatially bulky
substrates can be solved by screening and protein engineering [6]. Esters of carboxylic acids with
sterically-demanding ↵-substitutions are not easily hydrolysed by most of the lipases, and protein
engineering for making natural enzymes able to accept these substrates is still limited to relatively
bulky carboxylic acids [7]. Enzymatic hydrolysis of carboxylic acid esters having an ↵-quaternary
or ↵-tertiary centre is still a difficult task [8]; in contrast to the broad spectrum of esters with
bulky alcohol moieties accepted as substrates [9,10]. Activation by electron-withdrawing (EW)
hetero-atoms (e.g., O and N) or by EW-functional groups (e.g., -NO2, -CN, -CF3) is often required
to observe enzymatic hydrolytic activity [11–13]. ↵-,↵-Disubstituted malonate diesters are among
the few ↵-,↵-,↵-trisubstituted carboxylic esters accepted by carboxylesterases; in particular, pig
liver esterase (PLE) is particularly suited for catalyzing the enantioselective monohydrolysis
of differently substituted malonate diesters [14], including ester derivatives, such as dimethyl
3,3-dimethyl-2-methylenecyclohexane-1,1- dicarboxylate, a chiral building block used for the
enantioselective total synthesis of ent-kauranoids [15].
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In this work, we have studied the enzymatic hydrolysis of esters 1, derivatives of sterically
demanding 2,2-diaryl-2-hydroxy acids 2 (Figure 1); these molecules attract great attention for
pharmaceutical applications as they can be useful chiral building blocks for the synthesis of compounds
exerting muscarinic M3 receptor antagonist activity [16,17]. Antimuscarinic agents have a variety
of applications but one of the most well established is their use as inhaled bronchodilators for the
treatment of obstructive airway diseases such as asthma and chronic obstructive pulmonary disease
(COPD) [18]. The enzymatic hydrolysis of ester 1 has been therefore investigated as a possibly
suitable, affordable and sustainable method alternative to classical liquid (LC)/supercritical fluid
chromatography (SFC) chiral separation of racemic mixtures or diastereomeric salt crystallization,
to obtain the desired active (S)-enantiomer 2.
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Figure 1. Kinetic resolution of esters of 2,2-diaryl-2-hydroxy acids; optically pure acids are building
blocks for the synthesis of muscarinic receptor antagonists.
2. Results
2.1. Screening of Biocatalysts and Substrates
The synthesis of esters 1a-e, used in this work, was realized as described in Scheme 1.
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Scheme 1. Synthesis of esters 1a-e. Reaction conditions: a: THF, RT, 16 h; b: dihydrotoluene, 10% Pd/C,
EtOH, reflux, eight hours; c: (i) LiOH, THF/water, RT, 2 h; (ii) CDI, 2-(dimethylamino)ethanol, CH2Cl2,
60  C, 4 h; d: N-(benzyloxycarbonyl)-3-amino-1-propyl methanesulfonate, CsCO3, DMF, RT, 16 h.
Hydrolysis of 1a-b was firstly investigated using 20 commercial hydrolases and 15 enzymatic
preparations from our laboratory [19–24]; only commercial PLE gave hydrolysis of 1a,b (Scheme 2)
with conversions ranging between 50 and 100% after 24 h (Table 1).
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Table 1. Hydrolysis of 1a-b with pig liver esterase (PLE); Conditions: [S] = 2.5 mM, [PLE] = 7.5 mg/mL
in 100 mM phosphate buffer at pH = 7.0 and DMSO (5%), 30  C.
Entry Substrate Conv.(%) ee (R)-ester (%) ee (S)-acid (%) E Time (h)
1 1a 52 67 63 8 5
2 1a >97 <5 <5 - 24
3 1b 50 67 67 10 5
4 1b > 97 <5 <5 - 24
The reactions occurred with excellent rates, but low enantioselectivity, furnishing the S-acid
with enantiomeric ratio (E) ranging between 8 and 10. Absolute configurations were assigned by
comparison with enantiomerically pure sample previously synthesized [16]. Different (bulkier) alcohol
moieties were introduced with the aim of increasing the enantioselectivity, therefore esters 1c,d were
synthesized as shown before and used as substrates for the enzymatic hydrolysis with commercial
PLE, but enantioselectivity remained quite low (E < 8 in both the cases).
As a strategy for improving enantioselectivity, we synthesized 1e, where a benzyloxy
propylcarbamate was introduced as meta-substituent for boosting the structural diversity of the
two aromatic groups (Scheme 3).
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In fact, the kinetic resolution of 1e occurred with higher enantioselectivity (E = 21, entry 1, Table 2)
than what observed with 1a–d. Commercial PLE preparation is extracted from animal tissues and
composed by 6 different isoenzymes, each one potentially leading to different stereoselectivity [14,25];
therefore, we also tested the six isoforms as single recombinant enzymes (commercially available and
named ECS-PLE 01–06) for the hydrolysis of 1e (Table 2, entries 2-7).
Table 2. Hydrolysis of 1e with PLE; conditions: [S] = 2.5 mM, [PLE] 7.5 mg/mL in 100 mM phosphate
buffer at pH = 7.0 and DMSO (5%), 30  C.
Entry Substrate Conv. (%) ee (R)-ester (%) ee (S)-acid (%) E Time (h)
1 Crude PLEs 30 37 87 21 5
2 ECS-PLE01 <5 - - - 24
3 ECS-PLE02 <5 - - - 24
4 ECS-PLE03 19 8 30 <5 24
5 ECS-PLE04 8 - n.d. - 24
6 ECS-PLE05 <5 - - - 24
7 ECS-PLE06 37 51 87 24 24
The highest enantioselectivity was observed with the recombinant isoform ECS-PLE06 (entry 7,
Table 3), comparable with the one obtained with crude PLE, which, in turn, showed higher
specific activity.
2.2. Optimization
Crude PLE was therefore used for further optimization, carried out using an experimental design
(Multisimplex v2.0 (Multisimplex AB, Karlskrona, Sweden), previously used for optimizing the
conditions of different biotransformations [26]. The control variables were substrate and enzyme
concentration, pH, co-solvent (DMSO) concentration, and temperature. Productivity at 24 h and
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enantioselectivity were chosen as response parameters. Under optimized conditions ([S] = 3.5 mg/mL
(8 mM); [Enz] = 5.0 mg/mL; solvent 0.1 M phosphate buffer/DMSO 8%, pH = 7.0 at 25  C), where the
ratio between substrate and enzyme was reduced, the highest enantioselectivity (E = 28) was obtained,
but reaction rate slowed down. Under these conditions, enzymatic hydrolysis gave 2e with an ee of
90% after 24 h, in correspondence of 30% conversion.
As previously reported, the addition of co-solvents, which alter the solubility of the substrate,
may affect the enantioselectivity and the reaction rate of reactions catalyzed by crude PLE [14,27].
Consequently, we investigated the activity and the enantioselectivity on the hydrolysis of 1e with
crude PLE carried out under optimized conditions in the presence of the solvents listed in Table 3.
Table 3. Hydrolysis of 1e with PLE in the presence of different co-solvents. Conditions: [S] = 8 mM,
[PLE] = 5.0 mg/mL in 100 mM phosphate buffer at pH = 7.0 and co-solvents (amounts as indicated in
Table), 25  C. Results after 24 h.
Entry Co-solvent (% v/v) Conv. (%) ee (R)-ester (%) ee (S)-acid (%) E
1 none 30 23 90 23
2 EtOH (8) <5 - - -
3 iPrOH (8) <5 - - -
4 DMSO (8) 30 39 90 28
5 THF (8) 10 9 79 10
6 acetone (8) <5 - - -
7 Et2O (30) <5 - - -
8 toluene (30) <5 - - -
9 n-heptane (30) 22 25 90 21
10 isooctane (30) 25 30 88 21
Protic water-soluble co-solvents (EtOH and iPrOH, entries 2 and 3, Table 3) suppressed enzymatic
activity, whereas, DMSO (firstly chosen as co-solvent) was the only polar co-solvent with beneficial
effects (entry 4, Table 3). Detected activity and enantioselectivity in the presence of highly hydrophobic
solvents (n-heptane and isooctane, entries 9 and 10, Table 3) were lower than the ones obtained in water
containing 8% DMSO. Reactions performed in the presence of different concentrations of hydrophobic
solvents (10, 30, 50% v/v) did not show any significant differences.
Another way to influence the overall reactivity of organic substrates in aqueous enzymatic
reactions involves the use of cyclodextrins (CDX) [28]. CDX can modify the solubility of organic
compounds in water, while establishing diastereoisomeric interactions with chiral substrates; for these
reasons, different CDX were tested as additive in the enzymatic hydrolysis of 1e (Table 4).
Table 4. Hydrolysis of 1e with PLE in the presence of  -cyclodextrins; conditions: [S] = 8 mM,
[PLE] = 5.0 mg/mL, [CDX] 10 mM in 100 mM phosphate buffer and DMSO (8%) at pH = 7.0, 25  C.
Results after 24 h.
Entry  -Cyclodextrin Conv. (%) eeester (%) eeacid (%) E
1 underivatized 45 70 86 28
2 triacetyl 40 59 88 28
3 methyl 33 44 88 24
4 trimethylammonium 25 31 91 28
Cyclodextrins generally improved the reaction rates, with  -CDX showing the highest acceleration
(entry 1, Table 4). The screening shown in Table 5 was carried out using a slight excess of CDX over
the substrate, so we decided to explore the effect of different stoichiometric ratios between  -CDX
and substrate (Table 5), observing that no significant improvements were obtained above 1.25 ratio
 -CDX/substrate.
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Table 5. Hydrolysis of 1e with PLE in the presence of different amounts of  -cyclodextrin ( -CDX);
conditions: [S] = 8 mM [PLE] = 5.0 mg/mL, different amounts of  -CDX in 100 mM phosphate buffer
and DMSO (8%) at pH = 7.0, 25  C. Results after 24 h.
Entry Ratio [ -CDX]/[S] Conv. (%) eeester (%) eeacid (%) E
1 1 41 60 86 24
2 1.25 45 70 86 28
3 1.5 45 70 86 28
4 2 48 78 84 28
2.3. Preparative Biotransformation
A preparative biotransformation was thus performed starting from 150 mg of 1e (Figure 2) using
the best reaction conditions (entry 2, Table 5).
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enzymatic kinetic resolution of these bulky substrates. Firstly, esters having α-quaternary or α-
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Figure 2. Preparative kinetic resolution of 1e. Conditions. [S] = 8 mM, [PLE] = 5.0 mg/mL,
[ -CDX] = 10 mM in phosphate buffer (100 mM) and DMSO (8%) at pH = 7.0, 25  C.
The reaction was stopped in correspondence of 54% conversion (after 40 h), allowing for the
recovery and purification of 2e (67 mg) with an ee of 80%. This batch of optically-enriched 2e was
chemically methylated to give optically enriched 1e, which was subsequently hydrolysed with PLE,
furnishing 50 mg of optically pure (S)-2e. The overall results of this sequential kinetic resolution are
given in Scheme 4.
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3. Discussion
Sterically demanding 2,2-diaryl-2-hydroxy carboxylic acids are valuable chiral building blocks for
the synthesis of antimuscarinic agents [9]. Two major problems were encountered in the enzymatic
kinetic resolution of these bulky substrates. Firstly, esters having ↵-quaternary or ↵-tertiary center
show severe steric hindrance that hampers the approach to the active site; in fact, among the
different enzymes tested, PLE was the only enzyme active on these substrates. Besides, esters
of 2-hydroxy-2-(3-hydroxyphenyl)-2-phenylacetate (the ones considered here as key precursors
for antimuscarinic agents preparation) display poor stereo-discrimination due to the presence of
two aromatic groups, directly bound to the stereocenter, which differ only for the presence of
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a meta-substituent on one of the two aromatic rings. Derivative 1e, which bears a benzyloxy
propylcarbamate substituent in meta-position, gives sufficient stereo-differentiation for achieving
moderate-to-good enantioselectivity (E = 28). Moreover, the biotransformation was optimized by
choosing suited co-solvents (DMSO) and additives ( -CDX).
The preparative significance of this method was established by the expedient preparation of
optically pure (S)-2e on multi-milligram scale, using a sequential kinetic resolution approach.
4. Materials and Methods
All chemicals were from Sigma-Aldrich (Milano, Italy) and/or VWR International (Milano, Italy)
and used without further purification unless otherwise stated. Pig liver esterase was purchased
from Sigma-Aldrich (Milano, Italy). PLE isoforms were from Enzymicals (Greifswald, Germany).
 -Cyclodextrins were provided by Wacker-Chemie GmbH (Munchen, Germany). Anhydrous solvents
were purchased from Aldrich and used as received. “Brine” refers to a saturated aqueous solution
of NaCl. Unless otherwise specified, solutions of common inorganic salts used in workups are
aqueous solutions. Optically pure/enriched compounds, used as HPLC standards, were synthesised
as previously described [17].
4.1. Analyticals
HPLC analyses were performed with a Jasco PU-980 pump equipped with a UV–VIS detector
Jasco UV-975 (Easton, MD, USA). The NMR of 1H and 13C spectra were recorded in DMSO using
Bruker 600 MHz or 400 MHz spectrometer (Karlsruhe, Germany), equipped with a self-shielded
z-gradient coil 5 mm 1H/nX broad band probehead for reverse detection, deuterium digital lock
channel unit, quadrature digital detection unit with transmitter offset frequency shift. Chemical shifts
are reported as   downfield in parts per million (ppm) and referenced to tetramethylsilane (TMS) as
the internal standard in the 1H measurements. Coupling constants (J values) are given in hertz (Hz)
and multiplicities are reported using the following abbreviation (s = singlet, d = doublet, t = triplet,
q = quartet, m = multiplet, br = broad, nd = not determined). The pulse programs were taken from
the Varian and Bruker software libraries. The HRMS spectra were recorded on an Agilent instrument
(Santa Clara, CA, USA) using the Time-of-Flight Mass Spectrometry (TOF MS) technique. Specific
rotation of compounds was measured with a Polarimeter Perkin Elmer (model 241 or 341, Waltham,
USA) at sodium D-line (589 nm), 25  C, 1 dm path length. Reactions were monitored by TLC using
0.25 mmMerck silica gel plates (60 F254, Darmstadt, Germany). For chiral analysis the samples were
analysed using a chiral column for the separation of the enantiomers. HPLC analyses were carried
out on a Kromasil 5-Amycoat column 4.6 ⇥ 250 mm (CPS Analitica, Milan, Italy), 5 µm; mobile
phase: n-hexane:isopropanol:TFA 8:2:0.1%, flow rate 1 mL/min,   = 220 nm. Optically pure/enriched
compounds were chemically synthesised as chiral HPLC standards. Column chromatography was
performed on Merck silica gel 60 (0.063–0.2 mm).
4.2. Procedure for the Synthesis of methyl 2-(4-(benzyloxy)phenyl)-2-hydroxy-2-phenylacetate (1a)
To a solution of methyl 2-oxo-2-phenylacetate (12.83 mL, 91 mmol) in THF (Volume: 350 mL),
(4-(benzyloxy)phenyl)magnesium bromide (100 mL, 100 mmol) was added dropwise at 0  C over
30 min and stirred overnight at RT. Reaction was partitioned between AcOEt and saturated NaCl,
organic phase dried over Na2SO4 and evaporated. The oily residue was crystalized in Et2O to afford
methyl 2-(4-(benzyloxy)phenyl)-2-hydroxy-2-phenylacetate (15 g, 43.1 mmol, 47.4 % yield) as white
solid. 1H NMR (600 MHz, DMSO-d6;   ppm 7.24–7.44 (m, 11 H) 6.94–6.98 (m, 2 H) 6.91 (dt, J = 8.08,
1.15 Hz, 1 H) 6.67 (s, 1 H) 5.06 (s, 2 H) 3.71 (s, 3 H); 13C NMR (151 MHz, DMSO-d6)   ppm 173.97
(s, 1 C) 158.36 (s, 1 C) 145.33 (s, 1 C) 143.63 (s, 1 C) 137.45 (s, 1 C) 129.35 (s, 1 C) 128.88 (s, 1 C) 128.28
(s, 1 C) 128.25 (s, 1 C) 128.15 (s, 1 C) 127.92 (s, 1 C) 127.40 (s, 1 C) 120.06 (s, 1 C) 114.50 (s, 1 C) 113.84
(s, 1 C) 81.05 (s, 1 C) 69.70 (s, 1 C) 52.96 (s, 1 C). HRMS (ESI-TOF): Exact mass calculated for C22H20O4
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[M-H]- = 347.1289, Found: [M + NH4]+ = 366.1698. 1H NMR and 13C NMR spectra of 1a are reported
in Supplementary Materials (Figures S2 and S3, respectively).
4.3. Procedure for the Synthesis of methyl 2-hydroxy-2-(3-hydroxyphenyl)-2-phenylacetate (1b)
Methyl 2-(3-(benzyloxy)phenyl)-2-hydroxy-2-phenylacetate (1a) (200 mg, 0.574 mmol),
1-methylcyclohexa-1,4-diene (129 µl, 1.148 mmol) and Pd/C 10% wet (60 mg, 0.028 mmol) were
refluxed in EtOH (2870 µl) in a closed vessel at 80  C for 8 h, then the mixture filtered on PTFE
membrane and evaporated under reduced pressure. The resulting oil was recrystallized in a
mixture of cyclohexane/iPr2O to give methyl 2-hydroxy-2-(3-hydroxyphenyl)-2-phenylacetate (130 mg,
0.503 mmol, 88% yield) as a white powder. 1H NMR (600 MHz, DMSO-d6)   ppm 9.35 (s, 1 H) 7.32 (d,
J = 4.29 Hz, 4 H) 7.25–7.30 (m, 1 H) 7.11 (t, J = 7.87 Hz, 1 H) 6.74–6.77 (m, 1 H) 6.73 (dd, J = 1.67, 0.95 Hz,
1 H) 6.67 (ddd, J = 8.02, 2.41, 0.89 Hz, 1 H) 6.55 (s, 1 H) 3.71 (s, 3 H); 13C NMR ((151 MHz, DMSO-d6)  
ppm 174.14 (s, 1 C) 157.33 (s, 1 C) 145.20 (s, 1 C) 143.82 (s, 1 C) 129.17 (s, 1 C) 128.15 (s, 1 C) 127.81 (s, 1 C)
127.50 (s, 1 C) 118.08 (s, 1 C) 114.89 (s, 1 C) 114.70 (s, 1 C) 81.10 (s, 1 C) 52.87 (s, 1 C); HRMS (ESI-TOF):
Exact mass calculated for C15H14O4 [M-H]- = 257.0819, Found: [M + Na]+ = 281.0783. 1H NMR and
13C NMR spectra of 1b are reported in Supplementary Materials (Figures S4 and S5, respectively).
4.4. Procedure for the Synthesis of 2-(dimethylamino)ethyl
2-(3-(benzyloxy)phenyl)-2-hydroxy-2-phenylacetate (1c)
Methyl 2-(3-(benzyloxy)phenyl)-2-hydroxy-2-phenylacetate (1a) (5 g, 14.35 mmol) and LiOH
(1.031 g, 43.1 mmol) were dissolved in THF (Volume: 15 mL)/Water (Volume: 15.00 mL) and
stirred for 2 h at RT. Reaction was quenched by the addition on 1M HCl and extracted with AcOEt,
the organic phase was washed with aqueous NaCl and dried over Na2SO4 before being evaporated
under reduced pressure. The desired product 2-(3-(benzyloxy)phenyl)-2-hydroxy-2-phenylacetic
acid (2a) (5.1 g, 15.25 mmol, 106 % yield) was obtained as a yellowish foam, not isolated and used
as such for the following step. 2-(3-(Benzyloxy)phenyl)-2-hydroxy-2-phenylacetic acid (2a) (2.5 g,
7.48 mmol) and CDI (2.425 g, 14.95 mmol) were reacted for 5 min in DCM (Volume: 8 mL) prior the
addition of 2-(dimethylamino)ethanol (2.257 mL, 22.43 mmol). Reaction was stirred for 4 h at 60  C,
then partitioned between AcOEt and sat NaHCO3aq, washed twice with water, dried over Na2SO4
and evaporated under reduced pressure. The crude was chromatographed on silica gel by gradient
elution from 100 % AcOEt to AcOEt/MeOH (7N NH3) 90/10 in 12 CV to give 2-(dimethylamino)ethyl
2-(3-(benzyloxy)phenyl)-2-hydroxy-2-phenylacetate (1c) (1.02 g, 2.52 mmol, 33.6 % yield) as a yellowish
oil. 1H NMR (600 MHz, DMSO-d6)   ppm 7.23–7.44 (m, 12 H) 6.98–7.01 (m, 1 H) 6.92–6.96 (m, 2 H)
6.58 (s, 1 H) 5.05 (s, 2 H) 4.23 (t, J = 5.57 Hz, 2 H) 2.12 (s, 6 H); 13C NMR (151 MHz, DMSO-d6)  
ppm 173.34 (s, 1 C) 158.33 (s, 1 C) 145.30 (s, 1 C) 143.63 (s, 1 C) 137.47 (s, 1 C) 129.25 (s, 1 C) 128.87
(s, 1 C) 127.88 (s, 1 C) 127.54 (s, 1 C) 127.43 (s, 1 C) 120.21 (s, 1 C) 114.69 (s, 1 C) 113.80 (s, 1 C) 81.06
(s, 1 C) 69.69 (s, 1 C) 63.47 (s, 1 C) 57.42 (s, 1 C) 45.54 (s, 1 C). HRMS (ESI-TOF): Exact mass calculated
for C25H27O4N [M]+ = 405.1940, Found [M-H]+ = 406.2011 1H NMR and 13C NMR spectra of 1c are
reported in Supplementary Materials (Figures S6 and S7, respectively). 1H NMR and 13C NMR spectra
of 1c are reported in Supplementary Materials (Figures S6 and S7, respectively).
4.5. Procedure for the Synthesis of (1-benzylpiperidin-4-yl)methyl
2-(3-(benzyloxy)phenyl)-2-hydroxy-2-phenylacetate (1d)
2-(3-(benzyloxy)phenyl)-2-hydroxy-2-phenylacetic acid (2a) (2.5 g, 7.48 mmol) and CDI
(2.425 g, 14.95 mmol) were reacted for 5 min in DCM (Volume: 15 mL) prior the addition of
(1-benzylpiperidin-4-yl)methanol (2.3 g, 11.20 mmol). Reaction was stirred for 3 h at 60  C, then DMF
was added and the mixture was stirred at 80  C for 4 h. The mixture was partitioned between AcOEt
and an aqueous solution of NaHCO3, washed twice with water, dried over Na2SO4 and evaporated
under reduced pressure. The crude was chromatographed first on silica gel (gradient elution from
100 % AcOEt to AcOEt/MeOH (7N NH3) 90/10 in 10 CV), then by flash chromatography on a reverse
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phase: C18 column 60 g, from 100/0 A/B to 75/25 A/B, A: water/MeCN 95:5 + 0.1% HCOOH
B:MeCN/water 95:5 + 0.1% HCOOH, to obtain the desired product (1-benzylpiperidin-4-yl)methyl
2-(3-(benzyloxy)phenyl)-2-hydroxy-2-phenylacetate (1d) (715 mg, 1.371 mmol, 18.3 % yield) as a white
oil. 1H NMR (600 MHz, DMSO-d6)   ppm 7.20–7.42 (m, 16 H) 6.93–6.97 (m, 2 H) 6.90–6.93 (m, 1 H)
6.60 (s, 1 H) 5.05 (s, 2 H) 3.99 (d, J = 6.44 Hz, 2 H) 3.40 (br s, 2 H) 2.73 (br d, J = 10.01 Hz, 2 H) 1.76–1.92
(m, 2 H) 1.49–1.58 (m, 1 H) 1.47 (br d, J = 12.92 Hz, 2 H) 1.12 (br d, J = 12.16 Hz, 2 H); 13C NMR
(151 MHz, DMSO-d6)   ppm 173.40 (s, 1 C) 158.31 (s, 1 C) 145.33 (s, 1 C) 143.63 (s, 1 C) 137.46 (s,
1 C) 129.24 - 129.35 (m, 1 C) 129.16 (br s, 1 C) 128.85 (s, 1 C) 128.50–128.65 (m, 1 C) 128.23 - 128.31
(m, 1 C) 128.18 (s, 1 C) 128.04 (s, 1 C) 127.85–127.94 (m, 1 C) 127.42–127.56 (m, 1 C) 127.17–127.35 (m,
1 C) 120.14 (s, 1 C) 114.63 (s, 1 C) 113.84 (s, 1 C) 81.11 (s, 1 C) 69.79 (s, 1 C) 69.68 (s, 1 C) 62.75 (s, 1 C)
53.04 (s, 1 C) 40.58 (s, 1 C) 35.38 (s, 1 C) 28.62 (s, 1 C). HRMS (ESI-TOF): Exact mass calculated for
C34H35NO4 [M]+ = 521.2566, Found [M+H]+ = 522.2642-. To 1H NMR and 13C NMR spectra of 1d are
reported in Supplementary Materials (Figures S8 and S9, respectively).
4.6. Procedure for the Synthesis of methyl
2-(3-(3-(((benzyloxy)carbonyl)amino)propoxy)phenyl)-2-hydroxy-2-phenylacetate (1e)
Methyl 2-hydroxy-2-(3-hydroxyphenyl)-2-phenylacetate (2b) (570 mg, 2.207 mmol) and
3-(((benzyloxy)carbonyl)amino)propyl methanesulfonate (761 mg, 2.65 mmol) were dissolved
in DMF (6 mL), followed by the addition of CsCO3 (1079 mg, 3.31 mmol). The reaction
solution was stirred at room temperature overnight. The reaction mixture was quenched
adding water then extracted with EtOAc. The organic phase was dried over Na2SO4, filtered
and evaporated under reduced pressure. The crude was purified by flash chromatography
(25 g silica, from 20 to 50 % EtOAc in heptane) to obtain the desired product methyl
2-(3-(3-(((benzyloxy)carbonyl)amino)propoxy)phenyl)-2-hydroxy-2-phenylacetate (1e) (670 mg,
1.491 mmol, 67.5 % yield) as a colourless oil. 1H NMR (600 MHz, DMSO-d6)   ppm 7.27–7.39
(m, 11 H) 7.24 (t, J = 8.27 Hz, 1 H) 6.88–6.92 (m, 2 H) 6.82–6.88 (m, 1 H) 6.67 (s, 1 H) 5.02 (s, 2 H) 3.94 (t,
J = 6.28 Hz, 2 H) 3.72 (s, 3 H) 3.16 (q, J = 6.54 Hz, 2 H) 1.85 (quin, J = 6.51 Hz, 2 H); 13C NMR (151 MHz,
DMSO-d6)   ppm 173.97 (s, 1 C) 158.36 (s, 1 C) 145.33 (s, 1 C) 143.63 (s, 1 C) 137.45 (s, 1 C) 129.35 (s,
1 C) 128.88 (s, 1 C) 128.28 (s, 1 C) 128.25 (s, 1 C) 128.15 (s, 1 C) 127.92 (s, 1 C) 127.40 (s, 1 C) 120.06 (s,
1 C) 114.50 (s, 1 C) 113.84 (s, 1 C) 81.05 (s, 1 C) 69.70 (s, 1 C) 52.96 (s, 1 C). HRMS (ESI-TOF): Exact mass
calculated for C26H27NO6 [M-H]- = 448.1766, Found: [M+NH4]+ = 467.2177. 1H NMR and 13C NMR
spectra of 1a are reported in Supplementary Materials (Figures S10 and S11, respectively).
4.7. Enantiomeric Excess Determination
The enantiomeric excess (ee %) was determined by HPLC with a Kromasil 5-Amycoat column
4.6 ⇥ 250 mm, 5 µm, mobile phase: n-hexane:isopropanol:TFA 8:2:0.1%, flow rate 1 mL/min,
  = 220 nm. Retention times: (R)-1a 10.1 min; (S)-1a: 11.5 min; (R)-2a 20.7 min; (S)-2a: 34.6 min;
(S)-1b: 11.3 min; (R)-1b: 11.5 min; (S)-2b: 14.1 min; (R)-2b: 16.1 min; (R)-1e: 16.3 min; (S)-1e:
17.4 min; (R)-2e: 23.8 min; (S)-2e 29.1 min. Representative HPLC chromatograms are reported in
Supplementary Materials (Figure S18).
4.8. General Procedure for Biotransformations
Screening and optimization were carried out by performing reactions in 5 mL screw-capped
test tubes with a reaction volume of 2 mL. Preparative biotransformations were carried out at 25
and 150 mL scale. Substrates (2.5–10 mM) were dissolved in DMSO (final concentration 5%) and
added to phosphate buffer (100 mM, pH = 7). The reactions were started by the addition of the
enzyme. The mixture was then kept at fixed temperature under magnetic stirring. Samples of the
biotransformation mixture were withdrawn, diluted with an equal volume of water, acidified with
1 N HCl and extracted with eight volumes of EtOAc. The organic extract was then concentrated and
analysed by HPLC.
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4.8.1. (S)-2-(3-(Benzyloxy)phenyl)-2-hydroxy-2-phenylacetic acid (2a)
1H NMR (600 MHz, DMSO-d6)   ppm 12.20–13.89 (m, 1 H) 9.31 (s, 1 H) 7.36–7.39 (m, 2 H)
7.29–7.34 (m, 2 H) 7.24–7.29 (m, 1 H) 7.11 (t, J = 7.89 Hz, 1 H) 6.82 (br s, 1 H) 6.79–6.82 (m, 1 H) 6.66
(ddd, J = 8.05, 2.34, 1.03 Hz, 1 H) 5.48–6.50 (m, 1 H) 13C NMR (151 MHz, DMSO-d6)   ppm 175.14 (s,
1 C) 157.22 (s, 1 C) 145.55 (s, 1 C) 144.17 (s, 1 C) 129.00 (s, 1 C) 128.01 (s, 1 C) 127.59 (s, 1 C) 118.21 (s,
1 C) 114.86 (s, 1 C) 114.66 (s, 1 C) 80.63 (s, 1 C). HRMS (ESI-TOF): Exact mass calculated for C14H12O4
[M-H]- = 243.0663; Found: [M+Na]+ = 267.0626.
4.8.2. (S)-2-Hydroxy-2-(3-hydroxyphenyl)-2-phenylacetic acid (2b)
1H NMR (600 MHz, DMSO-d6)   ppm 13.21 (br s, 1 H) 7.41–7.45 (m, 2 H) 7.36–7.41 (m, 4 H)
7.23–7.35 (m, 5 H) 7.01–7.05 (m, 1 H) 6.93–7.00 (m, 2 H) 6.34 (s, 1 H) 5.05 (s, 2 H); 13C NMR (151 MHz,
DMSO-d6)   ppm 175.01 (s, 1 C) 158.31 (s, 1 C) 145.68 (s, 1 C) 143.96 (s, 1 C) 137.47 (s, 1 C) 129.20 (s,
1 C) 128.88 (s, 1 C) 128.28 (s, 1 C) 128.18 (s, 1 C) 128.13 (s, 1 C) 127.71 (s, 1 C) 127.50 (s, 1 C) 120.23 (s,
1 C) 114.72 (s, 1 C) 113.50 (s, 1 C) 80.61 (s, 1 C) 69.70 (s, 1C). HRMS (ESI-TOF): Exact mass calculated
for C21H18O4 [M-H]+ = 333.1132, Found: [M+NH4]- = 352.1541.
4.8.3. (S)-2-(3-(3-(((Benzyloxy)carbonyl)amino)propoxy)phenyl)-2-hydroxy-2-phenylacetic acid (2e)
1H NMR (600 MHz, DMSO-d6)   ppm 13.15 (br s, 1 H) 7.29–7.41 (m, 10 H) 7.25–7.29 (m, 1 H)
7.21–7.24 (m, 1 H) 6.92–6.97 (m, 2 H) 6.77–6.89 (m, 1 H) 6.31 (br s, 1 H) 5.01 (s, 2 H) 3.93 (t, J = 6.22 Hz,
2 H) 3.15 (q, J = 6.63 Hz, 2 H) 1.84 (quin, J = 6.51 Hz, 2 H); 13C NMR (151 MHz, DMSO-d6)   ppm
174.98 (s, 1 C) 158.50 (s, 1 C) 156.61 (s, 1 C) 145.71 (s, 1 C) 144.13 (s, 1 C) 137.71 (s, 1 C) 129.05–129.19
(m, 1 C) 128.81 (s, 1 C) 128.15–128.36 (m, 1 C) 128.08 (s, 1 C) 127.60–127.69 (m, 1 C) 127.47–127.58 (m,
1 C) 119.97 (s, 1 C) 114.29 (s, 1 C) 112.27–113.50 (m, 1 C) 80.59 (s, 1 C) 65.85 (s, 1 C) 65.12–65.56 (m, 1
C) 37.45–38.24 (m, 1 C) 29.64 (s, 1 C). HRMS (ESI-TOF): Exact mass calculated for C26H27NO6 [M]+ =
435.1682, Found [M+H]+ = 436.1754; [↵]D =  3.4 (CHCl3; c=1).
4.9. Procedure for the Synthesis of methyl
(S)-2-(3-(3-(((benzyloxy)carbonyl)amino)propoxy)phenyl)-2-hydroxy-2-phenylacetate (optically enriched 1e)
(S)-2-(3-(3-(((Benzyloxy)carbonyl)amino)propoxy)phenyl)-2-hydroxy-2-phenylacetic acid (100 mg,
0,23 mmol) obtained by biotranformation was dissolved in MeOH (1,5 mL) and slowly added SOCl2
(0,5 mL) at 0  C. The reaction mixture was refluxed at 70  C for 2 h, after which time it was cooled to RT.
MeOHwas removed in vacuum and the resulting residue was poured onto ice-H2O and extracted with
EtOAc. The combined organic extracts were washed with 10% NaHCO3, brine, dried over Na2SO4,
and evaporated to provide the product as a white solid (101 mg, 98% yield). 1H NMR (600 MHz,
DMSO-d6)   ppm 7.20–7.40 (m, 12 H) 6.84–6.86 (m, 1 H) 6.82–6.90 (m, 2 H) 6.65 (s, 1 H) 5.01 (s, 2 H)
3.93 (t, J = 6.22 Hz, 2 H) 3.72 (s, 3 H) 3.15 (q, J = 6.67 Hz, 2 H) 1.84 (quin, J = 6.54 Hz, 2 H); 13C NMR
(151 MHz, DMSO-d6)   ppm 172.50–174.93 (m, 1 C) 158.11–159.19 (m, 1 C) 155.83–157.71 (m, 1 C)
144.39–146.14 (m, 1 C) 143.20–144.08 (m, 1 C) 137.30–137.95 (m, 1 C) 129.20–129.50 (m, 1 C) 128.80 (br d,
J = 27.51 Hz, 1 C) 128.24 (s, 1 C) 128.20 (br d, J = 3.30 Hz, 1 C) 127.82–127.98 (m, 1 C) 127.29–127.52 (m,
1 C) 119.48–120.06 (m, 1 C) 113.96–114.24 (m, 1 C) 113.42 (s, 1 C) 81.06 (s, 1 C) 65.65 (s, 1 C) 65.51 (s, 1 C)
52.40 - 53.57 (m, 1 C) 37.02 - 38.35 (m, 1 C) 28.67–29.99 (m, 1 C); HRMS (ESI-TOF): Exact mass calculated
for C26H27NO6 [M-H]- = 448.1766, Found: [M+H]+ = 450.1913. 1H NMR and 13C NMR spectra of
optically enriched 1e are reported in Supplementary Materials (Figures S12 and S13, respectively).
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4344/9/2/113/s1,
Table S1: Control variables and initial levels considered for the optimization. Figure S1: Sequential optimization
of the PLE-catalysed hydrolysis of 1e. Figure S2: 1H NMR spectrum of 1a. Figure S3: 13C NMR spectrum of 1a.
Figure S4: 1H NMR spectrum of 1b. Figure S5: 13C NMR spectrum of 1b. Figure S6: 1H NMR spectrum of 1c.
Figure S7: 13C NMR spectrum of 1c. Figure S8: 1H NMR spectrum of 1d. Figure S9: 13C NMR spectrum of 1d.
Figure S10: 1H NMR spectrum of 1e. Figure S11: 13C NMR spectrum of 1e. Figure S12: 1H NMR spectrum of
(S)-2a. Figure S13. 13C NMR spectrum of (S)-2a. Figure S14: 1H NMR spectrum of (S)-2b. Figure S15. 13C NMR
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spectrum of (S)-2b. Figure S16: 1H NMR spectrum of (S)-2e. Figure S17. 13C NMR spectrum of (S)-2e. Figure S18:
Chiral HPLC of the hydrolysis of 1e to 2e catalysed by PLE.
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